Serina Therapeutics, Inc. cash flow statement
In fiscal 2025, Serina Therapeutics, Inc.'s operations generated −$18.0m of cash; it spent $59,000 on capital projects, leaving free cash flow of −$18.0m.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −6 | −8 | −10 | −8 | −8 | −6 | −2 | −17 | −18 |
| Depreciation and amortisation | 0 | 0 | 0 | 1 | — | — | 0 | 0 | 0 |
| Stock-based pay | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 3 | 4 |
| Capital spending | 0 | 0 | 1 | 0 | — | — | 1 | 0 | 0 |
| Free cash flow | −6 | −8 | −11 | −8 | — | — | −3 | −17 | −18 |
| Free cash flow after stock pay | −6 | −9 | −13 | −9 | — | — | −3 | −20 | −22 |
| Shares issued | 10 | 5 | — | — | 0 | — | — | — | — |
| Quarter | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −8,009 | −2,962 | −4,589 | −4,322 | −3,750 | −3,850 | −6,033 | −6,684 |
| Depreciation and amortisation | 0 | 0 | −38 | 0 | 0 | 0 | 51 | 36 |
| Stock-based pay | 458 | 1,096 | 988 | 956 | 890 | 999 | 948 | 1,051 |
| Capital spending | 0 | 3 | 5 | 0 | 46 | 13 | 0 | 28 |
| Free cash flow | −8,009 | −2,965 | −4,594 | −4,322 | −3,796 | −3,863 | −6,033 | −6,712 |
| Free cash flow after stock pay | −8,467 | −4,061 | −5,582 | −5,278 | −4,686 | −4,862 | −6,981 | −7,763 |
| Shares issued | — | — | — | 4,916 | — | — | — | — |
Compare with peers
- Celldex Therapeutics, Inc. cash flow
- Ibio, Inc. cash flow
- Lisata Therapeutics, Inc. cash flow
- AIM Immunotech Inc. cash flow
- Clene Inc. cash flow
Head to head: CLDX vs SERIBIO vs SERLSTA vs SER
More: Biotechnology stocks compared, Health Care sector, rankings of US companies